S. Kraemer

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective

S. Heres, R. Bergstrom, S. Kraemer, 2014, International clinical psychopharmacology.

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study

J. Haro, T. Treuer, S. Kraemer, 2015, BMC Psychiatry.

Relationship of Insight with Medication Adherence and the Impact on Outcomes in Patients with Schizophrenia and Bipolar Disorder: Results From A 1-Year European Outpatient Observational Study.

J. Haro, T. Treuer, S. Kraemer, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Epidemiology, Demographics, Triptan Contraindications, and Prescription Patterns of Patients with Migraine: A German Claims Database Study

A. Straube, A. Gendolla, S. Kraemer, 2021, Neurology and Therapy.

Prevalence of ADHD in nonpsychotic adult psychiatric care (ADPSYC): A multinational cross-sectional study in Europe

J. Thome, J. Ramos-Quiroga, S. Kraemer, 2015, BMC Psychiatry.

Comparative Effectiveness in Terms of Treatment Discontinuation of Orodispersable Versus. Standard Oral Olanzapine Tablets in Non-Adherent Patients: Results from a 1-Year European Outpatient Observational Study.

J. Haro, T. Treuer, S. Kraemer, 2014, Value in Health.

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder

J. Haro, A. Koyanagi, T. Treuer, 2017, Patient preference and adherence.

Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study

H. Grunze, H. Hundemer, C. Henneges, 2013, BMC Psychiatry.

Burden of illness and health care resource utilization in adult psychiatric outpatients with attention-deficit/hyperactivity disorder in Europe

C. Kan, E. Sobanski, S. Kraemer, 2016, Current medical research and opinion.

Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1‐year European observational study

F. Rouillon, B. Augendre-Ferrante, S. Kraemer, 2012, Human psychopharmacology.

Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study

T. Forst, H. Hundemer, S. Kraemer, 2011, BMC psychiatry.